About: Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
Creator	Du, Lanying Jiang, Shibo Perlman, Stanley Lu, Lu Xia, Shuai Channappanavar, Rudragouda Meyerholz, David
topic	covid:e690c113c207f132b7b68a38f53889109e65a166#this
Source	Medline; PMC
abstract	To gain entry into the target cell, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) uses its spike (S) protein S2 subunit to fuse with the plasma or endosomal membrane. Previous work identified a peptide derived from the heptad repeat (HR) 2 domain in S2 subunit, HR2P, which potently blocked MERS-CoV S protein–mediated membrane fusion. Here, we tested an HR2P analogue with improved pharmaceutical property, HR2P-M2, for its inhibitory activity against MERS-CoV infection in vitro and in vivo. HR2P-M2 was highly effective in inhibiting MERS-CoV S protein–mediated cell-cell fusion and infection by pseudoviruses expressing MERS-CoV S protein with or without mutation in the HR1 region. It interacted with the HR1 peptide to form stable α-helical complex and blocked six-helix bundle formation between the HR1 and HR2 domains in the viral S protein. Intranasally administered HR2P-M2 effectively protected adenovirus serotype-5–human dipeptidyl peptidase 4–transduced mice from infection by MERS-CoV strains with or without mutations in the HR1 region of S protein, with >1000-fold reduction of viral titers in lung, and the protection was enhanced by combining HR2P-M2 with interferon β. These results indicate that this combination regimen merits further development to prevent MERS in high-risk populations, including healthcare workers and patient family members, and to treat MERS-CoV–infected patients.
has issue date	2015-06-08(xsd:dateTime)
bibo:doi	10.1093/infdis/jiv325
bibo:pmid	26164863
has license	bronze-oa
sha1sum (hex)	e690c113c207f132b7b68a38f53889109e65a166
schema:url	https://doi.org/10.1093/infdis/jiv325
resource representing a document's title	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
has PubMed Central identifier	PMC4655857
has PubMed identifier	26164863
schema:publication	Journal of Infectious Diseases
resource representing a document's body	covid:e690c113c207f132b7b68a38f53889109e65a166#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/e690c113c207f132b7b68a38f53889109e65a166
is schema:about of	named entity 'fuse' named entity 'protein' named entity 'peptide' named entity 'human' named entity 'formation' named entity 'Intranasal' named entity 'HEALTHCARE WORKERS' named entity 'S PROTEIN' named entity 'INHIBITING' named entity 'IMPROVED' named entity 'IN VITRO' named entity 'STRAINS' named entity 'ANALOGUE' named entity 'HIGHLY' named entity 'DIPEPTIDYL PEPTIDASE 4' named entity 'TREAT' named entity 'ADMINISTERED' named entity 'ADENOVIRUS SEROTYPE' named entity 'PROPERTY' named entity 'PROTEIN ' named entity 'HR2' named entity 'FOLD' named entity 'MEDIATED' named entity 'MUTATIONS' named entity 'ITS' named entity 'ENHANCED' named entity 'CONTAINING' covid:arg/e690c113c207f132b7b68a38f53889109e65a166 named entity 'MERS-COV S PROTEIN' named entity 'ENTRY' named entity 'THESE' named entity 'USES' named entity 'DEVELOPMENT' named entity 'PROTECTIVE EFFECT' named entity 'REGIMENS' named entity 'FUSION INHIBITOR' named entity 'INTRANASAL' named entity 'MERS-COV' named entity 'RESULTS' named entity 'INTERFERON ' named entity 'STABLE' named entity 'IDENTIFIED' named entity 'PEPTIDE' named entity 'VIRAL' named entity '28S' named entity 'LUNG' named entity 'SUBUNIT' named entity 'RISK POPULATIONS' named entity 'INFECTION' named entity 'WORK' named entity 'FAMILY MEMBERS' named entity 'FORMATION' named entity 'HIGH-RISK' named entity 'ENDOSOMAL MEMBRANE' named entity 'SPIKE' named entity 'IN VIVO' named entity 'COMBINING' named entity 'TO PREVENT' named entity 'HR1' named entity 'COMPLEX' named entity 'HUMAN' named entity 'COMBINATION' named entity 'GAIN' named entity 'DOMAIN' named entity 'TO FORM' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'BLOCKED' named entity 'FUSE' named entity 'MUTATION' named entity 'MERS' named entity 'REDUCTION' named entity 'DERIVED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software